"The three-year data reinforce that Absorb may provide unique benefits not possible with metallic stents, including increases in the average area within the blood vessel, reduction in plaque and improved vessel movement over time," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands. "As the body of data and real-world experience increase for Absorb, we are seeing compelling evidence that a temporary scaffold that dissolves completely after doing its job represents the future of interventional cardiology treatment." 2Also, at a recent PCR meeting in Rotterdam, data were presented from the ABSORB EXTEND study, a single-arm trial evaluating Absorb in patients with more complex heart disease than the ABSORB trial. Data from 450 patients enrolled in this trial showed that the rates of MACE at one year were slightly lower than a comparative set of data with a best-in-class drug eluting stent at the same follow-up period. In an analysis of 119 patients with diabetes from the ABSORB EXTEND trial, rates of MACE were comparable between patients with and without diabetes, a promising finding as event rates are typically higher in patients with diabetes when compared to patients without diabetes.
New Data Reinforce Strong Long-Term Clinical Performance Of Abbott's Absorb™ Bioresorbable Vascular Scaffold
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.